J9144 Daratumumab, hyaluronidase-fihj - CanMED: HCPCS

Return Home

Home

SEER Data & Software

Observational Research in Oncology Toolbox

Medication Information

CanMED: HCPCS

Generic Name:

Daratumumab, hyaluronidase-fihj

Brand Name:

Darzalex Faspro

Strength:

10mg

HCPCS:

J9144

SEER*Rx Category:

Immunotherapy

Major Drug Class:

Monoclonal Antibody

Minor Drug Class:

CD38

Oral (Y/N):

No

FDA Approval Year:

2020

FDA Discontinuation Year:

CMS Effective Date:

Jan. 1, 2021

CMS Discontinuation Date:

Status:

In Use